Edwards Lifesciences Co. (NYSE:EW) Shares Bought by International Assets Investment Management LLC

International Assets Investment Management LLC raised its holdings in Edwards Lifesciences Co. (NYSE:EW) by 10,990.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 163,919 shares of the medical research company’s stock after buying an additional 162,441 shares during the period. International Assets Investment Management LLC’s holdings in Edwards Lifesciences were worth $10,817,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Crewe Advisors LLC acquired a new stake in shares of Edwards Lifesciences during the first quarter worth about $28,000. First Community Trust NA acquired a new stake in shares of Edwards Lifesciences during the second quarter worth about $29,000. Webster Bank N. A. acquired a new stake in shares of Edwards Lifesciences during the second quarter worth about $39,000. Peoples Bank KS acquired a new stake in shares of Edwards Lifesciences during the third quarter worth about $40,000. Finally, Versant Capital Management Inc increased its position in shares of Edwards Lifesciences by 206.3% during the second quarter. Versant Capital Management Inc now owns 484 shares of the medical research company’s stock worth $45,000 after purchasing an additional 326 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Price Performance

EW stock opened at $68.63 on Thursday. The firm has a 50 day moving average of $68.07 and a 200-day moving average of $77.92. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12. The company has a current ratio of 3.71, a quick ratio of 2.87 and a debt-to-equity ratio of 0.08. The company has a market cap of $41.36 billion, a price-to-earnings ratio of 29.58, a PEG ratio of 3.00 and a beta of 1.13.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The company had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. During the same period last year, the firm earned $0.59 EPS. The company’s revenue for the quarter was up 8.9% on a year-over-year basis. As a group, equities analysts expect that Edwards Lifesciences Co. will post 2.61 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on EW shares. Oppenheimer reiterated an “outperform” rating and set a $90.00 target price on shares of Edwards Lifesciences in a research report on Thursday, September 12th. Morgan Stanley reiterated an “equal weight” rating and set a $70.00 target price on shares of Edwards Lifesciences in a research report on Friday, October 11th. Baird R W lowered Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 25th. The Goldman Sachs Group lowered their price target on Edwards Lifesciences from $107.00 to $91.00 and set a “buy” rating on the stock in a report on Friday, July 26th. Finally, Evercore ISI lowered their price target on Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating on the stock in a report on Tuesday, October 1st. Sixteen investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Edwards Lifesciences currently has a consensus rating of “Hold” and an average price target of $75.67.

Insider Activity

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total transaction of $330,400.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at $3,101,530.88. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total transaction of $330,400.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at $3,101,530.88. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Daveen Chopra sold 1,250 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total value of $87,437.50. Following the transaction, the vice president now owns 29,333 shares of the company’s stock, valued at $2,051,843.35. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 16,250 shares of company stock worth $1,099,238. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.